Navigation Links
Cardiome meldet Veröffentlichung positiver Ergebnisse aus Vergleichsstudie von Vernakalant IV mit Propafenon und Flecainid
Date:9/24/2013

Patientenkollektiv eine wirksame und gut verträgliche Alternative zu Propafenon oder Flecainid", erklärte Dr. med. Diego Conde, Leiter der kardiovaskulären Notfallversorgung am Instituto Cardiovascular de Buenos Aires. "Die mit Vernakalant im Vergleich zu Propafenon oder Flecainid deutlich kürzer ausfallende Konversionszeit zu einem normalen Sinusrhythmus verkürzt auch den Krankenhausaufenthalt und könnte weitere Vorteile für Patienten mit sich bringen," so Dr. Conde weiter.

Patienten mit symptomatischem, jüngst ausgebrochenem Vorhofflimmern (von weniger als 48 Stunden Dauer) ohne strukturelle Herzerkrankung oder hämodynamische Instabilität kamen für die Studie infrage. Die Probanden erhielten eine einzige orale 600-mg-Dosis Propafenon (N=50), eine einzige orale 300-mg-Dosis Flecainid (N=50) oder Vernakalant IV (N=50) in Form einer ersten 3,0-mg/kg-Dosis über 10 Minuten. Hinzu kam eine zusätzliche 2-mg/kg-Dosis, sofern das Vorhofflimmern nicht innerhalb von 15 Minuten abgeklungen war. Nach 8 Stunden belief sich die Konversionsrate in den Propafenon- und Flecainid-Gruppen auf etwa 80 %. In der Vernakalant-Gruppe lag sie nach 2 Stunden schon bei 90 %. Nach 8 Stunden lag kein statistisch bedeutender Unterschied vor. Neben dem kürzeren Zeitintervall bis zur Kardioversion lagen bei Patienten, die mit Vernakalant IV behandelt wurden, im Median auch deutlich kürzere Krankenhausaufenthalte vor: 243 Minuten (Quartilsabstand [IQR], 190-276) gegenüber 422 Minuten (IQR, 341- 739) bei Patienten mit Propafenon-Behandlung und 410 Minuten (IQR, 330-727) bei Patienten mit Flecainid-Behandlung (p<0,01). Den Berichten zufolge traten keine unerwünschten Ereignisse auf.[1]

Referenzen:

  1. Conde, D. et al. Conversion of Recent-Onset Atrial Fibrillation: Which Drug is the Best
    '/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
2. Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the Sodium ferrocyanide ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... Europe, Asia, China, Japan etc. regions) industry analysis ...
(Date:11/21/2014)... and SAN DIEGO , Nov. 20, ... announced that President and CEO Marc Hedrick , M.D. will ... DATE:   Thursday, December 4, 2014 TIME:    11:15 ... here or paste this URL into your browser,s address ... investors pre-register to save time and receive event updates. ...
(Date:11/18/2014)... (PRWEB) November 17, 2014 ... open architecture blade-based and rackmount computing infrastructure, today ... K80 dual-GPU accelerator throughout its GPU-enabled blade server ... of the company’s latest proprietary 80-lane Gen3 PCIe ... discrete NVIDIA Tesla K80 dual-GPU accelerator cards in ...
(Date:11/18/2014)... 2014 American Process Inc. (Atlanta, ... a partnership with researchers at Georgia Institute of ... and the USDA’s Forest Products Laboratory to develop ... Nanocellulose is a rapidly emerging high performance nanomaterial ... is to replace heavy steel structures within cars, ...
Breaking Biology Technology:Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3
... , COLUMBIA, Md., Sept. 8 Martek Biosciences ... of judges on the United States Court of Appeals for the ... to a patent infringement lawsuit between Martek and Lonza, Ltd., Nutrinova ... The appeals involve Lonza,s U.S. sale and use of DHA ...
... $5 Million Loan Will Leverage $15 Million ... , HARRISBURG, Pa., Sept. 8 Early-stage life ... create quality jobs with the help of a state investment in ... "The life sciences are a growth sector for Pennsylvania," ...
... Inc. (TSX: ONC, NASDAQ: ONCY ), will present ... Renshaw 11th Annual Healthcare Conference on Thursday, September 10, ... at the New York Palace Hotel from September 9 to ... will be available at: http://www.wsw.com/webcast/rrshq15/oncy or on the ...
Cached Biology Technology:Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case 2Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case 3PA Helping Life Science Companies Secure Venture Capital Needed to Expand, Gov. Rendell Says 2Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference 2
(Date:11/4/2014)... the right time might actually help boost a species, ... in understanding animal populations, pest control and managing fish ... journal Trends in Ecology and Evolution , a ... kind of positive population effect an overall species experiences ... the size and developmental stage of the creatures that ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)... birth weight and preterm birth are linked to increased ... published in the American College of Rheumatology (ACR) journal, ... birth weight and pre-term babies were not at greater ... , According to the ACR, 27 million Americans ... OA. Symptoms of OA range from mild to severe ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Preterm, low birth-weight babies may need new hips in adulthood 2
... long been considered a major risk factor for cardiovascular ... risk, but the mechanisms of how arteries stave off ... the Perelman School of Medicine, University of Pennsylvania, Wistar ... that the protein apolipoprotein E (apoE) plays a major ...
... the Nowgen Schools Genomics Programme website launches with a range ... genetics in schools and colleges. , Developments in genetics research ... at a cost of $3 billion to sequencing a genome ... genetics in classroom education have remained relatively static. The pace ...
... Research led by Chu Chen, PhD, Associate Professor of Neuroscience ... enzyme called Monoacylglycerol lipase (MAGL) as a new therapeutic target ... online November 1, 2012 in the Online Now section of ... that inactivation of MAGL, best known for its role in ...
Cached Biology News:Softening arteries, protecting the heart 2Softening arteries, protecting the heart 3Bridging the gap between genomics and education 2LSUHSC research identifies new therapeutic target for Alzheimer's disease 2
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
BACE (CT) rabbit polyclonal antibody...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Biology Products: